BCRX Q1 2018 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-57.9% YoY

Gross Profit

$4M96.5% margin

Operating Income

-$22M-558.7% margin

Net Income

-$26M-648.3% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+2.2%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$155M

Total Liabilities

$93M

Stockholders' Equity

$62M

Cash & Equivalents

$44M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$9M	-57.9%
Gross Profit	$4M	$9M	-58.0%
Operating Income	-$22M	-$11M	-107.9%
Net Income	-$26M	-$14M	-81.3%

Revenue Segments

Royalty

$4M92%

Collaborative and Other Research and Development

$315,0008%